LCM
VYNE icon

Laurion Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Laurion Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-178
Closed -$481K – 1612
2018
Q1 		$481K Buy
+178
New +$433K ﹤0.01% 1021

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Laurion Capital Management's VYNE Position: Q2 2018 in Review

Laurion Capital Management sold out of VYNE Therapeutics (VYNE) in Q2 2018, closing a stake of 178 shares — an estimated $481K sold.

Laurion Capital Management first reported a position in VYNE in Q1 2018 and held it in 1 quarter. The position peaked at $481K in Q1 2018. 48 funds tracked by Wall St. Rank hold VYNE as of Q2 2018.

  • Laurion Capital Management reported no remaining VYNE Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Laurion Capital Management sold 178 VYNE Therapeutics shares in Q2 2018, an estimated $481K.
  • Laurion Capital Management first reported a position in VYNE Therapeutics in Q1 2018 and held it in 1 quarter.
  • Laurion Capital Management's VYNE Therapeutics position peaked at $481K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2018.

Based on Laurion Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.